Artelo Biosciences Announces Selection of Aptus Clinical Ltd. as Clinical Research Organization for Phase 1b/2a Study of ART27.13 Oct 29, 2019 8:30am EDT
Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference Oct 22, 2019 9:00am EDT
Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine Sep 18, 2019 8:00am EDT
Artelo Biosciences to Present at the Fall Investor Summit in New York City on September 17th Sep 11, 2019 9:00am EDT
Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update Jul 15, 2019 4:01pm EDT
Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option Jun 25, 2019 1:00pm EDT
Artelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq Jun 21, 2019 1:50pm EDT
Artelo Biosciences Retains Crescendo Communications, LLC for Investor Relations Services May 08, 2019 4:05pm EDT
Artelo Biosciences Retains Maxim Group LLC to Provide Financial Advisory and Investment Banking Services Jan 03, 2019 8:00am EST
New Preclinical Cell-Line Data of Artelo Biosciences' ART27.13 Demonstrate Anti-Proliferative Activity in Tumor Models Oct 09, 2018 8:00am EDT
